|Articles|February 11, 2016
Biotech Selects Almac's Interactive Response Platform
A global biotech will be migrating to its newest generation Interactive Response Technology (IRT), platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Advertisement
Almac Clinical Technologies, part of the Almac Group, has announced that a global biotechnology company will be migrating to its newest generation Interactive Response Technology (IRT), IXRS® 3 platform for the upcoming build of 15 clinical studies across multiple therapeutic areas in early 2016.
Read the
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership
2
Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies
3
Breaking the Efficacy Ceiling in IBD and Beyond
4
The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research
5